Cryotherapy With Dynamic Intermittent Compression Improves Recovery From Revision Total Knee Arthropla	sty PubMed	- NCB

11/27/2018

PubMed

Format: Abstract

•

Full text links
ELSEVIER

<u>J Arthroplasty.</u> 2017 Sep;32(9):2788-2791. doi: 10.1016/j.arth.2017.03.052. Epub 2017 Mar 31.

# Cryotherapy With Dynamic Intermittent Compression Improves Recovery From Revision Total Knee Arthroplasty.

Murgier J<sup>1</sup>, Cailliez J<sup>1</sup>, Wargny M<sup>2</sup>, Chiron P<sup>1</sup>, Cavaignac E<sup>1</sup>, Laffosse JM<sup>1</sup>.

**Author information** 

# Abstract

**BACKGROUND:** The goal of this study was to assess the efficacy of cryotherapy with dynamic intermittent compression (CDIC) in relieving postoperative pain, decreasing blood loss, and improving functional scores after revision total knee arthroplasty (rTKA).

**METHODS:** We conducted a prospective case-control study (level of evidence: I) to evaluate the efficacy of CDIC on postoperative bleeding, pain, and functional outcomes after rTKA. Forty-three cases were included at a single institution and divided in 2 groups: a control group without CDIC (n = 19) and an experimental group with CDIC (n = 24). Bleeding was evaluated by calculating total blood loss, pain at rest was evaluated with a visual analog scale on postoperative day 3, and function was assessed using the Oxford score at 6 months postoperatively. The comparative analysis was performed using the Fisher exact test.

**RESULTS:** The CDIC group had significantly lower total blood loss (260 vs 465 mL; P < .05), significantly less pain on day 3 (1 vs 3; P < .05), and a significantly higher functional score (42 vs 40; P < .05) than the control group.

**CONCLUSION:** This is the first report dealing with the use of CDIC after rTKA. According to our results, it improves the recovery of patients who underwent rTKA; thus, it should be integrated into our daily practice.

Copyright © 2017 Elsevier Inc. All rights reserved.

KEYWORDS: arthroplasty; blood loss; compressive cryotherapy; knee; pain

PMID: 28465126 DOI: 10.1016/j.arth.2017.03.052

[Indexed for MEDLINE]

MeSH terms

LinkOut - more resources

# **Accepted Manuscript**

Cryotherapy with Dynamic Intermittent Compression Improves Recovery from Revision Total Knee Arthroplasty


J. Murgier, J. Cailliez, M. Wargny, P. Chiron, E. Cavaignac (, J.M. Laffosse

PII: \$0883-5403(17)30289-9 DOI: 10.1016/j.arth.2017.03.052


Reference: YARTH 55778

To appear in: The Journal of Arthroplasty

Received Date: 17 February 2017
Revised Date: 9 March 2017
Accepted Date: 22 March 2017



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



# Cryotherapy with Dynamic Intermittent Compression Improves Recovery from Revision Total Knee Arthroplasty

Effectiveness of cryotherapy with dynamic intermittent compression in rTKA

- J. Murgier\* (1), J. Cailliez (1), M. Wargny (2), P. Chiron, E. Cavaignac (1), JM. Laffosse (1)
  - (1) Département de chirurgie Orthopédique et Traumatologique, CHU Toulouse, Toulouse, France
  - (2) Epidemiology Department, CHU Toulouse, Toulouse, France

# \*Corresponding author:

Dr Murgier Jérôme
Département d'Orthor

Département d'Orthopédie Traumatologie

CHU Toulouse - Hôpital Pierre Paul Riquet

Place du Docteur Baylac, TSA 40031

31059 Toulouse Cedex 9, France

Email: murgier.jerome@hotmail.fr

Tel: 0561775582

Fax:0561775432

**Conflict of interest:** No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

1 2 3	Cryotherapy with Dynamic Intermittent Compression Improves Recovery from Revision Total Knee Arthroplasty
4 5	Effectiveness of cryotherapy with dynamic intermittent compression in rTKA
6 7 8	ABSTRACT
9	Purpose: The goal of this study was to Assess the efficacy of cryotherapy with dynamic
LO	intermittent compression (CDIC) in Relieving post operative pain, decreasing blood loss
l1	and improving functional scores after revision total knee arthroplasty (rTKA).
12	Methods: we conducted a prospective case-control study. (Level of evidence: I) to
13	evaluate the efficacy of CDIC on postoperative bleeding, pain and functional outcomes after
<b>L</b> 4	rTKA. 43 cases were included at a single institution and divided in two groups: a control
15	group without CDIC (n = 19) and an experimental group with CDIC (n = 24).Bleeding was
16	evaluated by calculating total blood loss; pain at rest was evaluated with a visual analogue
17	scale (VAS) on postoperative day 3; function was assessed using the Oxford score at 6
18	months postoperative. The comparative analysis was performed using Fisher's exact test
19	<b>Results:</b> The CDIC group had significantly lower total blood loss (260 ml vs 465 ml, $P <$
20	0.05), significantly less pain on day 3 (1 vs 3, $P < 0.05$ ) and a significantly higher functional
21	score (42 vs 40, $P < 0.05$ ) than the control group.
22	Conclusion: This is the first report dealing with the use of CDIC after rTKA. According to
23	our results, it improves the recovery of patients who underwent revision TKA, thus it should
24	be integrated into our daily practice.
25 26 27 28 29 30	
, 1	

# INTRODUCTION

33

32

34 35

36 37 38

43

44 45 46

47 48 49

with its inherent risks [23]. Revision TKA is a major orthopaedic procedure that causes soft tissue damages which contribute to localised pain, which in turn reduces range of motion and causes persistent quadriceps atrophy [25]. Significant blood loss after this procedure (up to 1.5 L) can lead to systemic complications [23]. Despite progress in

associated with a higher risk of infection [7], of patient dissatisfaction [9] and postoperative blood transfusion

Revision total knee arthroplasty (rTKA) procedures cause blood loss. Postoperative anaemia is

multimodal analgesia and anaesthetic methods, knee arthroplasty is a painful surgery [25]. Non-pharmacological treatments can also play a role, most notably cryotherapy which decreases the local metabolism, thereby reducing blood loss and pain [13]. This technique has minimal disadvantages relative to its potential benefits

New devices that combine cryotherapy with dynamic intermittent compression (CDIC) have recently been introduced. These devices provide a dry cold and maintain a consistent temperature for an extended period of time [24, 25]. While the benefits of these systems were demonstrated in primary TKA [24] and anterior cruciate ligament reconstruction [17], we did not find any published studies evaluating the effect of CDIC in patients undergoing revision TKA.

Our hypothesis was that use of CDIC would reduce total blood loss after revision TKA. The main objective of this study was to assess its efficacy in terms of postoperative blood loss. Patients who underwent rTKA were split into two matched groups for comparisons: one group with CDIC and the other one without. The other objectives were to compare the blood transfusion rate, the pain, the functional scores and the complication rate in both groups.

54

# PATIENTS AND METHODS

This was a single-institution, prospective case-control study (Level of evidence: III). It was approved by our hospital's research ethics committee (Number 01-0115).

# **Patients**

61 All patien

All patients who underwent single-stage rTKA from January 2013 to January 2015 were included.

Patients were excluded when a two-stage revision or a partial revision was performed. They were also excluded if they had a contraindication to CDIC, such as history of deep vein thrombosis, a coagulation disorder or skin damage at the device application site.

Forty-three patients were included (27 males, 16 females). The revisions procedures were carried out with a rotating hinge knee prosthesis (RHK Nexgen®, Zimmer, Warsaw, USA) in all cases. A tibial tubercle osteotomy was needed in 9 cases and the patella was resurfaced in 14 cases during the revision procedure.

The anaesthesia and postoperative analgesia protocols used were standardised and similar in the two groups. Anticoagulant therapy was initiated 6 hours after the end of surgery in all patients.

The procedure was performed with a tourniquet in all cases. It was released before closing the wound to realize complete haemostasis. The mean procedure duration was 120 minutes (90–140).

# Methods

The population was divided into two groups: a control group without CDIC and an experimental one with CDIC. The demographics data in these two groups were comparable (Table 1). The patients in the control group were included between January 2013 and April 2014. The patients in the CDIC group were included between May 2014 and January 2015.

The CDIC device used was the Game Ready® system (CoolSystems Inc., Concord, CA, USA). It comes with an anatomical wrap that is applied to the knee. This wrap circulates pre-cooled compressed air and water. The temperature-controlled unit generates a dry cold; this is more comfortable for the patient than wet cold, thereby limiting the risk of maceration, bandage deterioration and skin lesions. The wrap is covered with a removable, washable cover for the patient's health and comfort. The wrap is connected to a portable control unit. The compression is applied intermittently depending on the protocol selected. The surgery support staff was given specific training on how to use the CDIC.

The following protocol was used:

Application: after bandaging, in the operating room and before transfer to recovery room

Intensity: programme 3 (30 minute on/off cycles)

Temperature: 8°C

- Application duration: two 8-hour cycles over a 24-hour period

- Treatment duration: 72 hours postoperative

The control group was treated with regular cold application (4 hours per day) using a cold pack.

The following parameters were measured in both groups: total blood loss, haemoglobin and haematocrit levels on D-1, D+1 and D+5, transfusion volume and rate (red cell concentrate (RCC) units), pain on postoperative day 3, functional outcomes based on the Oxford score at 6 months postoperative and the number of complications recorded at 6 months postoperative.

Total blood loss was calculated using the preoperative (D-1) and postoperative (D+5) laboratory test results according to the Merculiari formula [8]:

Total blood loss = VST x (Hct<sub>pre</sub>-Hct<sub>post D5</sub>) + volume of retransfused RCC\* where the patient's total blood volume =  $k_1 \times \text{height (m)}^3 + k_2 \times \text{mass (kg)} + k_3$ 

for men:  $k_1 = 0.3669$ ,  $k_2 = 0.03219$ , and  $k_3 = 0.6041$ ;

and for women:  $k_1 = 0.3561$ ,  $k_2 = 0.03308$ , and  $k_3 = 0.1833$ 

Hct<sub>pre</sub> = initial preoperative Hct

 $Hct_{post D5} = Hct$  on the morning of the 5<sup>th</sup> postoperative day

When transfusion was done (allogenic or autologous), the total blood loss was equal to the blood loss calculated from the change in haematocrit plus the volume transfused [14].

The indication for RCC transfusion in our surgical unit is standardised to Hb < 8 g/dL and/or patient with symptomatic anaemia.

Postoperative pain at rest was measured by the surgery unit's nurse using a visual analogue scale (VAS) on the 3rd day postoperative and by looking at the cumulative morphine use on the 5th postoperative day, expressed in morphine-equivalent dose (in mg).

The Oxford score [4] was collected pre- and postoperatively using the validated French version of the questionnaire [5]. The questionnaire was filled out during a follow-up visit 6 months after the procedure.

# Statistical analysis

Cohort characteristics are presented as numbers, means, SDs, and ranges. The normal distribution of the data was assessed using the Kolmogorov-Smirnov test. For variables that were not normally distributed, data were analysed using the Mann-Whitney test for independent samples and the Wilcoxon signed rank test for dependent samples. Comparison of observed proportions was performed using Fisher's exact test. Statistical analysis was carried out using SPSS 18 Statistical Software (SPSS Inc, Chicago, IL, USA) and significance was set at *P* less than 0.05.

# RESULTS (Table2)

# Bleeding

The total blood loss was lower in the CDIC group than in the control group (260 ml vs 465 ml, P < 0.05). The haemoglobin and haematocrit levels were similar between groups. The transfusion rate was lower in the CDIC group (8% vs 42%, P < 0.05) and the mean lowest Haemoglobin level was lower in the control group with 8.5 gm/dL (+/- 1,2) vs 9,6 (+/- 1,6); p < 0,005. In the CDIC group, the number of RCC units given per patient was lower as well. No differences were found in any of the other measured blood-related parameters.

4	2	^
- 1	~	
		v

## **Pain**

Pain at rest on day 3 was lower in the CDIC group than in the control group (1 vs 3, P < 0.05). The cumulative morphine intake at day 5 was not significantly different between groups.

## Functional scores at 6 months

The Oxford score at 6 months postoperative was higher in the CDIC group than in the control group (42 vs 40).

# Complications

There were four complications in the CDIC group and three in the control group. There were two cases of infection recurrence and one case of deep vein thrombosis in each group, and one case of extensor mechanism disruption in the CDIC group.

# 

# **DISCUSSION**

Our hypothesis was confirmed. The patients in the CDIC group had lower total blood loss than patients in the control group. Moreover, the transfusion rate and the pain were lower in the CDIC group. The functional outcome was similar between the two groups at 6 months postoperative.

This is the first study to evaluate the use of CDIC after revision TKA. The blood loss was evaluated using a method previously validated for revision TKA patients [22]. This method provides a complete view of the total blood loss, as it also takes into account hidden blood loss following TKA [23]. We did not use the blood volume present in the suction drains, as in other studies [16]. This blood loss calculation method is not reliable; it overestimates blood losses and can lead to more blood transfusions [19]. The volume of blood in surgical drains has never been validated as being an objective measure of blood loss [22]. There is no correlation between the volume of blood in the drains and the need for transfusion [15].

CDIC has been used in the sports medicine setting to improve recovery and to treat ligament and bone injuries [15, 17]. It has been shown that CDIC improves postoperative recovery by stimulating the tissue repair process [3]. Generally, these systems are provided to healthy athletes undergoing a minor procedure compared to revision TKA. We believe that any help is beneficial to a fragile population such as the one undergoing revision TKA.

The contribution of CDIC to postoperative recovery from TKA has already been demonstrated. Su et al [24] evaluated CDIC in patients undergoing primary TKA and compared it to a control group. In that study, the patients in the CDIC group used the system for 5 days after the procedure. They found a lower narcotic intake and slight improvement in the functional outcome in the patients using CDIC. We also found a tendency of reduced narcotic use (-20 mg morphine-equivalents in the CDIC group). This reduced narcotic intake reduces

the side effects inherent to these agents. Patients feel less medicated and have a better postoperative course. Advanced cryotherapy was compared to icing only in the postoperative course of TKA in a randomised controlled trial [25]. The authors concluded that there were no advantages in using advanced cryotherapy in daily practice, particularly because of the additional cost associated with these systems. However, more than one kind of cryotherapy system was used in that study, leading to variability in the results. Moreover, the blood loss was measured only through haemoglobin variations, which does not take into account hidden blood loss [23]. Additionally, no blood transfusions were performed, as the patients were undergoing primary TKA. The need for transfusion is higher during revision TKA [2].

Other therapeutic means have been proposed to reduce bleeding during primary and revision TKA procedures. Tranexamic acid has been shown to be effective in hip and knee arthroplasty [1]. Use of thrombin-based topical haemostatics does not have clear-cut benefits. One group has described its benefits in revision TKA [22]; however, anaemia, atrial fibrillation, infection have been associated with this type of product [12, 16, 18, 21]. These side effects do not come into play when using CDIC. Thienport et al [25] bring up the risk of frostbite in the area where CDIC is applied. This is an extremely serious complication that would require an additional major soft tissue procedure [6]. We have not encountered this complication, and have not found any documented cases of frostbite with CDIC.

The current study has certain limitations. Firstly, this was a multi-surgeon study which increases the variability of the results. However, this also means that the study can be more easily generalised to current practice. Secondly, this study was performed within a highly specialised TKA surgery unit. Because of the use of advanced anaesthesia procedures, analgesic infiltration and preventative multimodal pain management [11], it is possible that a type II error occurred in our interpretation of the results. However, the anaesthesia and analgesia techniques did not differ between the control and CDIC groups. Moreover, the transfusion rate – likely the most relevant criteria from a clinical point of view – is subjected to confounding factors because of the patients' comorbidities. Although we use a standardised approach, this bias is still present.

Conclusion

The number of revision TKA procedures performed each year will continue to increase [10, 20, 22]. Since CDIC improves the recovery of patients undergoing revision TKA, it should be integrated into our daily practice. Prospective randomised trial is necessary to validate the results of our study.

206		
207 208		REFERENCES
209 210 211	1.	Alshryda S, Sukeik M, Sarda P, et al (2014) A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement. Bone Joint J 96-B:1005-1015.
212 213	2.	Berman AT, Geissele AE, Bosacco SJ (1988) Blood loss with total knee arthroplasty. Clin Orthop Relat Res 137–138.
214 215 216	3.	Dahl J, Li J, Bring DK-I, et al (2007) Intermittent pneumatic compression enhances neurovascular ingrowth and tissue proliferation during connective tissue healing: a study in the rat. J Orthop Res 25:1185–1192.
217 218	4.	Dawson J, Fitzpatrick R, Carr A, Murray D (1996) Questionnaire on the perceptions of patients about total hip replacement. J Bone Joint Surg Br 78:185–190.
219 220 221	5.	Delaunay C, Epinette J-A, Dawson J, et al (2009) Cross-cultural adaptations of the Oxford-12 HIP score to the French speaking population. Orthop Traumatol Surg Res 95:89–99.
222 223	6.	Dundon JM, Rymer MC, Johnson RM (2013) Total patellar skin loss from cryotherapy after total knee arthroplasty. J Arthroplasty 28:376.e5–7.
224 225 226	7.	Freedman J, Luke K, Monga N, et al (2005) A provincial program of blood conservation: The Ontario Transfusion Coordinators (ONTraC). Transfus Apher Sci 33:343–349.
227 228	8.	Gibon E, Courpied J-P, Hamadouche M (2013) Total joint replacement and blood loss: what is the best equation? Int Orthop 37:735–739.
229 230 231	9.	Ishida K, Tsumura N, Kitagawa A, et al (2011) Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty. Int Orthop 35:1639–1645.
232 233 234	10.	Jeserschek R, Clar H, Aigner C, et al (2003) Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery: a prospective, double-blind, randomised and placebo-controlled study. J Bone Joint Surg Br 85:174–177.
235 236	11	Kehlet H, Thienpont E (2013) Fast-track knee arthroplasty status and future challenges. Knee 20 Suppl 1:S29–33.
237 238 239	12.	Kim HJ, Fraser MR, Kahn B, et al (2012) The efficacy of a thrombin-based hemostatic agent in unilateral total knee arthroplasty: a randomized controlled trial. J Bone Joint Surg Am 94:1160–1165.
240 241 242	13	Kullenberg B, Ylipää S, Söderlund K, Resch S (2006) Postoperative cryotherapy after total knee arthroplasty: a prospective study of 86 patients. J Arthroplasty 21:1175–1179.

243 244	14	Liu X, Zhang X, Chen Y, et al (2011) Hidden blood loss after total hip arthroplasty. J Arthroplasty 26:1100–5.e1. doi: 10.1016/j.arth.2010.11.013
245 246 247	15	Mesa-Ramos F, Mesa-Ramos M, Maquieira-Canosa C, Carpintero P (2008) Predictors for blood transfusion following total knee arthroplasty: a prospective randomised study. Acta Orthop Belg 74:83–89.
248 249 250	16.	Mozet C, Prettin C, Dietze M, et al (2012) Use of Floseal and effects on wound healing and pain in adults undergoing tonsillectomy: randomised comparison versus electrocautery. Eur Arch Otorhinolaryngol 269:2247–2254.
251 252 253	17	Murgier J, Cassard X (2014) Cryotherapy with dynamic intermittent compression for analgesia after anterior cruciate ligament reconstruction. Preliminary study. Orthop Traumatol Surg Res 100:309–312.
254 255	18.	Nasso G, Piancone F, Bonifazi R, et al (2009) Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg 88:1520–1526.
256 257	19.	Parker MJ, Livingstone V, Clifton R, McKee A (2007) Closed suction surgical wound drainage after orthopaedic surgery. Cochrane Database Syst Rev CD001825.
258 259	20.	Rasouli MR, Harandi AA, Adeli B, et al (2012) Revision total knee arthroplasty: infection should be ruled out in all cases. J Arthroplasty 27:1239–43.e1–2.
260 261 262	21.	Renkens KL, Payner TD, Leipzig TJ, et al (2001) A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. Spine 26:1645–1650.
263 264 265 266	22.	Romanò CL, Monti L, Logoluso N, et al (2014) Does a thrombin-based topical haemostatic agent reduce blood loss and transfusion requirements after total knee revision surgery? A randomized, controlled trial. Knee Surg Sports Traumatol Arthrosc.
267 268 269	23.	Sehat KR, Evans RL, Newman JH (2004) Hidden blood loss following hip and knee arthroplasty. Correct management of blood loss should take hidden loss into account. J Bone Joint Surg Br 86:561–565.
270 271 272	24.	Su EP, Perna M, Boettner F, et al (2012) A prospective, multi-center, randomised trial to evaluate the efficacy of a cryopneumatic device on total knee arthroplasty recovery. J Bone Joint Surg Br 94:153–156.
273 274	25.	Thienpont E (2014) Does advanced cryotherapy reduce pain and narcotic consumption after knee arthroplasty? Clin Orthop Relat Res 472:3417–3423.
275		
276		
277		

Table 1 Baseline characteristics and surgery related data for the cohort TT: tibial tubercle, BMI: Body mass index, ASA: American Society of Anesthesiologists

		Control group (n=19)	CDIC group (n=24)	P
Baseline	Mean (SD) Age, years	66.5 (9.7)	70 (13.9)	0.86
characteristics	Sex ratio: F/M	8/11	8/16	0.78
	Mean (SD) BMI, kg/m <sup>2</sup>	29.7 (4.6)	29.7 (4.7)	0.89
	Pré op anticoagulants, n (%)	6 (32)	3 (13)	0.15
	ASA score, n (%)	1: 1 (5) 2: 8 (42)	1: 4 (17) 2: 14 (58)	0.17
		3: 10 (53)	3: 6 (25)	
Surgery-related	Mean (SD) Surgery time, min	120 (40.2)	118 (43.3)	0.84
data	Mean (SD) Tourniquet time	98 (27.4)	100 (29.3)	0.98
	TT osteotomy, n (%)	5 (26)	4 (17)	0.48
	Patella resurfacing, n (%)	8(42)	6(25)	0.39

Table 2 Summary of variables measured in both groups.

RCC: red cell concentrate, Hb: haemoglobin, Hct: haematocrit, VAS: visual analogue scale

		Control group (n=19)	CDIC group (n=24)	P
<b>Blood loss</b>	Mean (SD) Hb at D-1 (g/dL)	12.5 (2.1)	13 (1.8)	0.76
	Mean (SD) Hb at D+5 (g/dL)	10.4 (1.2)	10.7 (1.3)	0.31
	Mean (SD) Hct at D-1 (%)	37 (5.9)	39.6 (4.9)	0.9
	Mean (SD) Hct at D+5 (%)	31 (3.6)	32.7 (3.6)	0.19
	Mean (SD) Total blood loss (ml)	465 (275)	260 (106)	0.024
	Mean lowest Hb level	8.5	9.6	0.03
	Transfusion rate	42%	8%	0.013
Transfusion	Number of RCC units	0: 58% (n=11) 1: 5% (n=1) 2: 26% (n=5) 3: 11% (n=2)	0: 92% (n=22) 1: 0% (n = 0) 2: 4% (n=1) 3: 4% (n=1)	0.023
Pain	Mean (SD) VAS Day +3	3 (1)	1(1)	0.01
	Mean (SD) Narcotic consumption at Day +5 (mg)	100 (37)	80 (37)	1
Functional score	Mean (SD) Oxford	40 (2.8)	42 (2.4)	NS